BHC (Bausch Health Companies Inc)
Insider Trading Activity
Every open-market purchase and sale reported by BHC officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-20 | Aimee J. Lenar | President, US Pharma | F | — | — |
| 2026-07-17 | Aimee J. Lenar | President, US Pharma | F | — | — |
| 2026-07-15 | STEVEN HYOSIG LEE | SVP, Controller & CAO | F | — | — |
| 2026-07-02 | AMY B WECHSLER | Director | A | — | — |
| 2026-07-02 | SANDRA LEUNG | Director | A | — | — |
| 2026-07-02 | John Paulson | Director | A | — | — |
| 2026-05-26 | Frank D. Lee | Director | A | — | — |
| 2026-05-26 | Christian A Garcia | Director | A | — | — |
| 2026-05-26 | MICHAEL GOETTLER | Director | A | — | — |
| 2026-05-26 | SANDRA LEUNG | Director | A | — | — |
| 2026-05-26 | ROBERT N POWER | Director | A | — | — |
| 2026-05-26 | EIRY ROBERTS | Director | A | — | — |
| 2026-05-26 | SARAH B KAVANAGH | Director | A | — | — |
| 2026-05-26 | AMY B WECHSLER | Director | A | — | — |
| 2026-05-26 | John Paulson | Director | A | — | — |
| 2026-05-20 | Frank D. Lee | Director | Sell | — | — |
| 2026-04-02 | SANDRA LEUNG | Director | A | — | — |
| 2026-04-02 | AMY B WECHSLER | Director | A | — | — |
| 2026-04-02 | John Paulson | Director | A | — | — |
| 2026-03-03 | THOMAS APPIO | Chief Executive Officer | MIXED | — | — |
| 2026-03-03 | Jean-Jacques Charhon | EVP, CFO | F | — | — |
| 2026-03-03 | Seana Carson | EVP, General Counsel | MIXED | — | — |
| 2026-02-27 | THOMAS APPIO | Chief Executive Officer | MIXED | — | — |
| 2026-02-27 | STEVEN HYOSIG LEE | SVP, Controller & CAO | A | — | — |
| 2026-02-27 | Seana Carson | EVP, General Counsel | MIXED | — | — |
| 2026-02-27 | Jean-Jacques Charhon | EVP, CFO | MIXED | — | — |
| 2026-02-27 | Aimee J. Lenar | EVP, US Pharma | MIXED | — | — |
| 2026-02-11 | Seana Carson | EVP, General Counsel | A | — | — |
| 2026-02-11 | THOMAS APPIO | Chief Executive Officer | A | — | — |
| 2026-01-02 | AMY B WECHSLER | Director | A | — | — |
| 2026-01-02 | SANDRA LEUNG | Director | A | — | — |
| 2026-01-02 | John Paulson | Director | A | — | — |
| 2025-11-28 | PAULSON & CO. INC. | 10%+ Owner | Buy | — | — |
| 2025-10-06 | John Paulson | Director | — | — | — |
| 2025-10-02 | John Paulson | Director | A | — | — |
| 2025-10-02 | SANDRA LEUNG | Director | A | — | — |
| 2025-10-02 | AMY B WECHSLER | Director | A | — | — |
| 2025-09-08 | Seana Carson | EVP, General Counsel | MIXED | — | — |
| 2025-08-22 | Frank D. Lee | Director | Sell | — | — |
| 2025-08-14 | John Paulson | Director | Buy | — | — |
| 2025-08-13 | John Paulson | Director | Buy | — | — |
| 2025-07-29 | SANDRA LEUNG | Director | A | — | — |
| 2025-07-29 | MICHAEL GOETTLER | Director | A | — | — |
| 2025-07-18 | Aimee J. Lenar | EVP, US Pharma | A | — | — |
| 2025-07-16 | Aimee J. Lenar | EVP, US Pharma | F | — | — |
| 2025-07-15 | STEVEN HYOSIG LEE | SVP, Controller & CAO | A | — | — |
| 2025-07-02 | BRETT ICAHN | Director | A | — | — |
| 2025-07-02 | AMY B WECHSLER | Director | A | — | — |
| 2025-07-02 | John Paulson | Director | A | — | — |
| 2025-06-17 | John Paulson | Director | Buy | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 73,686,111 | — |
| — | 10%+ Owner | 73,255,869 | — |
| — | Director | 17,960,285 | — |
| — | Director | 16,993,250 | — |
| — | Director | 16,983,241 | — |
| — | Chief Executive Officer | 3,453,236 | — |
| — | CHAIRMAN & CEO | 1,395,371 | — |
| — | EVP, General Counsel | 782,932 | — |
| — | EVP, CFO | 706,478 | — |
| — | EVP, Chief Financial Officer | 564,933 | — |
| — | EVP and CFO | 446,137 | — |
| — | Director | 387,207 | — |
| — | President, US Pharma | 371,680 | — |
| — | Director | 314,979 | — |
| — | Director | 300,594 | — |
| — | Director | 282,230 | — |
| — | Director | 239,224 | — |
| — | President, Ortho-Dermatologics | 235,035 | — |
| — | Director | 225,279 | — |
| — | Director | 220,280 | — |
| — | SVP, Controller & CAO | 197,364 | — |
| — | EVP AND GENERAL COUNSEL | 162,240 | — |
| — | Director | 161,516 | — |
| — | Director | 155,616 | — |
| — | Director | 135,578 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BHC quote page; the site-wide leaderboard is on the insider transactions hub.